Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status

Medical Oncology

Volumn 17, Issue 2, 2000, Pages 106-110

  Janinis, Jim ^a   Efstathiou, E ^a   Panopoulos, C ^a   Samantas, E ^a   Aravantinos, G ^a   Christodoulou, Ch ^b   Skarlos, D ^b  

^a AGII ANARGIRI CANCER HOSPITAL   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

Author keywords

High grade gliomas; Phase II study; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TOXICITY; GLIOMA; HUMAN; MALE; NERVOUS SYSTEM TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034048257     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02796204     Document Type: Article

References (13)

1. 1 Louis DN, Cavenee WK. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 5th edn. Lippincott Raven: New York, 1997, pp 2013-2022.
2. 2 Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
3. 3 Sanson M et al. Treatment of recurrent malignant supratentorial gliomas with Ifosfamide, Carboplatin, and Etoposide: a phase II study. Eur J Cancer 1996; 32A(13): 2229-2235.
4. 4 Denny BJ, Wheelhoouse RT, Stevens MFG, Tsang LLH, Slack JA. NMR and molecular modelling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33: 9045-9051.
5. 5 Broch CS et al. Demonstration and quantitation of temozolomide uptake in vivo in human brain tumors. Proc 9th NCI-EORTC Symp on New Drugs in Cancer Therapy, Amsterdam, The Netherlands. Kluwer Academic Publishers, Dordrecht 1996, p 137 (abstract).
6. 6 Levin V et al. Temodal at first relapse in anaplastic astrocytoma patients. J Neurooncol 1997; 35(Suppl 1), S1: 31.
7. 7 Bower M et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother Pharmacol 1997; 40(6): 484-488.
8. 8 Newlands ES et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996; 32A: 2236-2241.
9. 9 O'Reilly SM et al. Temozolomide a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 1993; 29A: 940-942.
10. 10 O'Soba D et al. Health related quality of life benefits in patients with recurrent anaplastic astrocytoma (AA) treated with temozolomide. Proc Am Soc Clin Oncol 1998; 17: 388.
11. 11 Newlands ES, Rustin GJS, Evans H, Wedge SR, Brampton MH. Phase I trial of oral temozolomide administered over 6 and 7 weeks. Proc 9th NCI-EORTC Symp on New Drugs in Cancer Therapy, Amsterdam, The Netherlands. ASCO Publications 1996, p 345 (abstract).
12. 6-alkylguanine DNA alkyltransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer. Clinical Pharmacology. Proc Am Soc Clin Oncol 1996; 15: 366 (abstract).
13. 6-alkylguanine DNA alkyltranferase directed DNA repair. Proc Am Soc Clin Oncol 1996; 15: 362 (abstract).